Redwood AI Corp. (CSE: AIRX) (OTCQB: RDWCF) (Frankfurt: Y0N) (WKN: A422EZ) announced that its common shares have been approved for electronic clearing and settlement through the Depository Trust Company (DTC), a move expected to simplify trading for U.S. investors and enhance liquidity. CEO Louis Dron stated that DTC eligibility improves access for U.S. investors and brokerage firms by enabling more efficient electronic clearing and settlement.
The company also announced it has engaged InvestorBrandNetwork (IBN) to provide market awareness, corporate communications and digital media services, including editorial coverage, newsletter distribution, social media support and podcast syndication through Sept. 30, 2026, or until the allocated budget is exhausted. Redwood will pay IBN an aggregate cash fee of $114,000 for the services, with no securities issued as compensation.
Redwood AI uses advanced artificial intelligence to accelerate chemistry R&D, with the aim of assisting in drug discovery and development, and furthering defense and safety solutions. The company combines expertise in chemistry, AI, and manufacturing to streamline drug synthesis and scale-up. Redwood AI’s platform is designed to enable faster, more efficient development of new therapies and chemistry-driven applications. For more information, visit Redwood AI.
This DTC eligibility is significant for Redwood AI as it removes barriers for U.S. investors, potentially broadening the shareholder base and increasing trading volume. The engagement with IBN, a specialized communications platform within the Dynamic Brand Portfolio, aims to raise awareness among investors and the general public. IBN offers access to a vast network of wire solutions, editorial syndication to 5,000+ outlets, and social media distribution to millions of followers. This campaign is expected to enhance Redwood AI’s visibility in the competitive AI and biotech sectors.
The implications of this announcement are twofold: improved liquidity through DTC eligibility and increased market awareness through IBN’s services. These developments could attract more institutional and retail investors, supporting Redwood AI’s growth in accelerating chemistry R&D. The cash fee arrangement without stock issuance also signals a disciplined approach to shareholder value. As Redwood AI advances its AI-driven drug discovery platform, these strategic moves position the company for broader recognition and potential partnerships in the pharmaceutical and defense industries.
